Immunomic Therapeutics, Inc. Appoints Robert Newman as Chief Business Officer

Immunomic Therapeutics, Inc. announced the appointment of Robert Newman as Chief Business Officer. He brings over thirty years of global experience in the biopharmaceutical industry, including numerous executive roles with operational oversight of many key functions including corporate development, sales and marketing and drug development.

Immunomic Therapeutics, Inc. (ITI) is a privately held clinical stage biotechnology company pioneering the study of nucleic acid immunotherapy platforms. These investigational technologies have the potential to alter how we use immunotherapy for cancer, allergies, and animal health.